

Jack F M Wetzels

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2706347/publications.pdf>

Version: 2024-02-01

348
papers

18,409
citations

10389

72
h-index

18647

119
g-index

357
all docs

357
docs citations

357
times ranked

16428
citing authors

#	ARTICLE	IF	CITATIONS
1	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, S1-S276.	5.2	782
2	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. <i>Kidney International</i> , 2011, 79, 1331-1340.	5.2	609
3	Cardiovascular and Noncardiovascular Mortality Among Patients Starting Dialysis. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1782.	7.4	584
4	Age and Association of Kidney Measures With Mortality and End-stage Renal Disease. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2349.	7.4	493
5	Risk HLA-DQA1 and PLA ₂ R1 Alleles in Idiopathic Membranous Nephropathy. <i>New England Journal of Medicine</i> , 2011, 364, 616-626.	27.0	442
6	Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1286-1291.	4.5	320
7	Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1735-1743.	6.1	270
8	Serum hepcidin: reference ranges and biochemical correlates in the general population. <i>Blood</i> , 2011, 117, e218-e225.	1.4	246
9	Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1049-1058.	5.0	245
10	Comparison of three methods for isolation of urinary microvesicles to identify biomarkers of nephrotic syndrome. <i>Kidney International</i> , 2010, 78, 810-816.	5.2	228
11	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 128-139.	11.4	223
12	Tracing the Origin of Glomerular Extracapillary Lesions from Parietal Epithelial Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2604-2615.	6.1	218
13	Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. <i>European Heart Journal</i> , 2018, 39, 1535-1542.	2.2	218
14	Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1909-1913.	0.7	200
15	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 115-127.	11.4	199
16	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 268-280.	5.2	198
17	Immunochemical and Mass-Spectrometry-Based Serum Heparin Assays for Iron Metabolism Disorders. <i>Clinical Chemistry</i> , 2010, 56, 1570-1579.	3.2	190
18	Proximal tubular cells contain a phenotypically distinct, scattered cell population involved in tubular regeneration. <i>Journal of Pathology</i> , 2013, 229, 645-659.	4.5	188

#	ARTICLE	IF	CITATIONS
19	Parietal Epithelial Cells Participate in the Formation of Sclerotic Lesions in Focal Segmental Glomerulosclerosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1262-1274.	6.1	186
20	Angiotensin II Contributes to Podocyte Injury by Increasing TRPC6 Expression via an NFAT-Mediated Positive Feedback Signaling Pathway. <i>American Journal of Pathology</i> , 2011, 179, 1719-1732.	3.8	180
21	Macroalbuminuria Is a Better Risk Marker than Low Estimated GFR to Identify Individuals at Risk for Accelerated GFR Loss in Population Screening. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2582-2590.	6.1	176
22	Renal Progenitor Cells Contribute to Hyperplastic Lesions of Podocytopathies and Crescentic Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2593-2603.	6.1	173
23	The multifaceted role of iron in renal health and disease. <i>Nature Reviews Nephrology</i> , 2020, 16, 77-98.	9.6	167
24	Membranous nephropathy. <i>Nature Reviews Disease Primers</i> , 2021, 7, 69.	30.5	167
25	Association of Variants at UMOD with Chronic Kidney Disease and Kidney Stones—Role of Age and Comorbid Diseases. <i>PLoS Genetics</i> , 2010, 6, e1001039.	3.5	166
26	Association of Anti-PLA2R Antibodies with Outcomes after Immunosuppressive Therapy in Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1386-1392.	4.5	152
27	Conversion of Urine Protein-to-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-to-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis. <i>Annals of Internal Medicine</i> , 2020, 173, 426-435.	3.9	144
28	Estimating Glomerular Filtration Rate. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 899-906.	4.5	138
29	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295.	5.2	135
30	Treatment with Vitamin D and Calcium Reduces Bone Loss after Renal Transplantation: A Randomized Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1608-1614.	6.1	132
31	Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. <i>Kidney International</i> , 2008, 74, 1568-1576.	5.2	130
32	Minimal change disease and idiopathic FSGS: manifestations of the same disease. <i>Nature Reviews Nephrology</i> , 2016, 12, 768-776.	9.6	125
33	Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2729-2737.	6.1	125
34	Idiopathic Membranous Nephropathy: Outline and Rationale of a Treatment Strategy. <i>American Journal of Kidney Diseases</i> , 2005, 46, 1012-1029.	1.9	122
35	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. <i>Nature Communications</i> , 2020, 11, 1600.	12.8	120
36	Serum creatinine is a poor marker of GFR in nephrotic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 707-711.	0.7	118

#	ARTICLE	IF	CITATIONS
37	Urinary Excretion of \hat{I}^{22} -Microglobulin and IgG Predict Prognosis in Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 169-174.	6.1	117
38	Long-Term Outcome of Biopsy-Proven, Frequently Relapsing Minimal-Change Nephrotic Syndrome in Children. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1593-1600.	4.5	117
39	Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. <i>Clinica Chimica Acta</i> , 2013, 421, 213-218.	1.1	117
40	Hepatocyte Nuclear Factor $1\hat{I}^{26}$ Associated Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 345-353.	6.1	117
41	Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers?. <i>Kidney International</i> , 1998, 53, 1559-1573.	5.2	116
42	Extending Prednisolone Treatment Does Not Reduce Relapses in Childhood Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 149-159.	6.1	113
43	Uremic Toxins Inhibit Transport by Breast Cancer Resistance Protein and Multidrug Resistance Protein 4 at Clinically Relevant Concentrations. <i>PLoS ONE</i> , 2011, 6, e18438.	2.5	113
44	Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 718-728.	11.4	110
45	Genetic causes of focal segmental glomerulosclerosis: implications for clinical practice. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 882-890.	0.7	109
46	Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1746-1755.	6.1	109
47	Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. <i>Kidney International</i> , 1991, 40, 1171-1176.	5.2	108
48	Phospholipase A2 Receptor (PLA2R1) Sequence Variants in Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 677-683.	6.1	108
49	The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. <i>Kidney International</i> , 2014, 85, 636-640.	5.2	106
50	The parietal epithelial cell is crucially involved in human idiopathic focal segmental glomerulosclerosis ¹¹ See editorial by Schwartz, p. 1894.. <i>Kidney International</i> , 2005, 68, 1562-1572.	5.2	104
51	Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. <i>Kidney International</i> , 2009, 76, 44-53.	5.2	104
52	Treatment of idiopathic membranous nephropathy. <i>Nature Reviews Nephrology</i> , 2013, 9, 443-458.	9.6	104
53	The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. <i>Kidney International</i> , 2021, 99, 986-998.	5.2	104
54	Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 848-853.	0.7	99

#	ARTICLE	IF	CITATIONS
55	The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 711-714.	0.7	97
56	The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery. <i>Kidney International</i> , 2019, 96, 1292-1302.	5.2	97
57	Management of patients with membranous nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 6-9.	0.7	92
58	Nurse Practitioner Care Improves Renal Outcome in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 390-398.	6.1	90
59	The Clinician and Estimation of Glomerular Filtration Rate by Creatinine-based Formulas. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 937-950.	4.5	88
60	Introduction of the CKD-EPI equation to estimate glomerular filtration rate in a Caucasian population. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3176-3181.	0.7	87
61	Urinary Excretion of Glutathione S Transferases Alpha and Pi in Patients with Proteinuria: Reflection of the Site of Tubular Injury. <i>Nephron</i> , 2000, 85, 120-126.	1.8	85
62	Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. <i>Transplantation</i> , 2003, 76, 821-826.	1.0	85
63	Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1142-1148.	0.7	83
64	Mycophenolate Mofetil in Idiopathic Membranous Nephropathy: A Clinical Trial With Comparison to a Historic Control Group Treated With Cyclophosphamide. <i>American Journal of Kidney Diseases</i> , 2007, 50, 248-256.	1.9	82
65	Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2207-2216.	0.7	82
66	Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. <i>Clinical Pharmacokinetics</i> , 2019, 58, 859-874.	3.5	82
67	Detection of Activated Parietal Epithelial Cells on the Glomerular Tuft Distinguishes Early Focal Segmental Glomerulosclerosis from Minimal Change Disease. <i>American Journal of Pathology</i> , 2014, 184, 3239-3248.	3.8	81
68	Cancer Risk after Cyclophosphamide Treatment in Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1066-1073.	4.5	80
69	The Parietal Epithelial Cell: A Key Player in the Pathogenesis of Focal Segmental Glomerulosclerosis in Thy-1.1 Transgenic Mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 928-939.	6.1	78
70	Reducing Renal Uptake of Radiolabeled Peptides Using Albumin Fragments. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1506-1511.	5.0	78
71	Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2010.	7.4	78
72	Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population epidemiology and outcome. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 186-192.	0.7	77

#	ARTICLE	IF	CITATIONS
73	Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease. <i>Kidney International</i> , 2012, 82, 710-717.	5.2	77
74	Epidemiology of Contrast Material–induced Nephropathy in the Era of Hydration. <i>Radiology</i> , 2012, 263, 706-713.	7.3	77
75	RECURRENCE OF TYPE I MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS AFTER RENAL TRANSPLANTATION. <i>Transplantation</i> , 1997, 63, 1628-1633.	1.0	76
76	Validation of the kidney failure risk equation in European CKD patients. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1773-1779.	0.7	75
77	Drug-Induced Nephrotoxicity Aetiology, Clinical Features and Management. <i>Drug Safety</i> , 1991, 6, 131-147.	3.2	72
78	Recurrent focal glomerulosclerosis: natural course and treatment with plasma exchange. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 2650-2656.	0.7	72
79	Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2450-2453.	0.7	71
80	Serum suPAR in patients with FSGS: trash or treasure?. <i>Pediatric Nephrology</i> , 2013, 28, 1041-1048.	1.7	71
81	Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort. <i>Pediatric Nephrology</i> , 2017, 32, 139-150.	1.7	71
82	Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1756-1769.	6.1	71
83	Long-Term Outcomes in Idiopathic Membranous Nephropathy Using a Restrictive Treatment Strategy. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 150-158.	6.1	70
84	Clinical evaluation of analytical variations in serum creatinine measurements: why laboratories should abandon Jaffe techniques. <i>BMC Nephrology</i> , 2012, 13, 133.	1.8	69
85	Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. <i>Kidney International</i> , 2019, 95, 666-679.	5.2	68
86	Serum-soluble urokinase receptor concentration in primary FSGS. <i>Kidney International</i> , 2012, 81, 1043-1044.	5.2	67
87	Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 3062-3071.	0.7	67
88	Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1002-1009.	0.7	66
89	Low-Molecular-Weight Proteins as Prognostic Markers in Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2846-2853.	4.5	65
90	Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, iv131-iv141.	0.7	65

#	ARTICLE	IF	CITATIONS
91	High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3581-3588.	0.7	63
92	Gelatin-based plasma expander effectively reduces renal uptake of ¹¹¹ In-octreotide in mice and rats. <i>Journal of Nuclear Medicine</i> , 2006, 47, 528-33.	5.0	63
93	Active proteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1. <i>Journal of Pathology</i> , 2013, 229, 660-671.	4.5	62
94	Glucose Specifically Regulates TRPC6 Expression in the Podocyte in an AngII-Dependent Manner. <i>American Journal of Pathology</i> , 2014, 184, 1715-1726.	3.8	62
95	Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. <i>Journal of Nuclear Medicine</i> , 2006, 47, 432-6.	5.0	62
96	Subtotal Ablation of Parietal Epithelial Cells Induces Crescent Formation. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 629-640.	6.1	61
97	Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. <i>Pediatric Nephrology</i> , 2019, 34, 2261-2277.	1.7	60
98	Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease. <i>American Journal of Kidney Diseases</i> , 2014, 63, 446-455.	1.9	59
99	Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up. <i>Kidney International</i> , 2015, 87, 1263-1264.	5.2	59
100	Abdominal aortic calcification in patients with CKD. <i>Journal of Nephrology</i> , 2017, 30, 109-118.	2.0	59
101	Familial glomerulonephritis characterized by massive deposits of fibronectin. <i>American Journal of Kidney Diseases</i> , 1995, 25, 781-791.	1.9	58
102	Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2852-2857.	0.7	58
103	Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 129-136.	0.7	55
104	Optimized Metabolomic Approach to Identify Uremic Solutes in Plasma of Stage 3-4 Chronic Kidney Disease Patients. <i>PLoS ONE</i> , 2013, 8, e71199.	2.5	55
105	Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplantation. <i>Transplant International</i> , 2004, 17, 151-157.	1.6	54
106	Long-Term Outcome After Cyclophosphamide Treatment in Children With Steroid-Dependent and Frequently Relapsing Minimal Change Nephrotic Syndrome. <i>American Journal of Kidney Diseases</i> , 2007, 49, 592-597.	1.9	54
107	Initial Implementation of a Web-Based Consultation Process for Patients With Chronic Kidney Disease. <i>Annals of Family Medicine</i> , 2013, 11, 151-156.	1.9	53
108	Therapeutic trials in adult FSGS: lessons learned and the road forward. <i>Nature Reviews Nephrology</i> , 2021, 17, 619-630.	9.6	53

#	ARTICLE	IF	CITATIONS
109	Long-Term Treatment with Tenofovir: Prevalence of Kidney Tubular Dysfunction and Its Association with Tenofovir Plasma Concentration. <i>Antiviral Therapy</i> , 2014, 19, 765-771.	1.0	52
110	A Novel Hypokalemic-Alkalotic Salt-Losing Tubulopathy in Patients with CLDN10 Mutations. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3118-3128.	6.1	52
111	CD44 is required for the pathogenesis of experimental crescentic glomerulonephritis and collapsing focal segmental glomerulosclerosis. <i>Kidney International</i> , 2018, 93, 626-642.	5.2	52
112	Elevated Skeletal Muscle Blood Flow in Noncomplicated Type 1 Diabetes Mellitus. <i>Hypertension</i> , 1999, 34, 1080-1085.	2.7	51
113	Proximal tubular efflux transporters involved in renal excretion of p-cresyl sulfate and p-cresyl glucuronide: Implications for chronic kidney disease pathophysiology. <i>Toxicology in Vitro</i> , 2015, 29, 1868-1877.	2.4	51
114	Renal Handling of Circulating and Renal-Synthesized Hepcidin and Its Protective Effects against Hemoglobin α -Mediated Kidney Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2720-2732.	6.1	50
115	Immunological remission in PLA2R-antibody α -associated membranous nephropathy: cyclophosphamide versus rituximab. <i>Kidney International</i> , 2018, 93, 1016-1017.	5.2	50
116	Beta-2-microglobulin is superior to N-acetyl-beta-glucosaminidase in predicting prognosis in idiopathic membranous nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2546-2551.	0.7	48
117	In mpkCCD cells, long-term regulation of aquaporin-2 by vasopressin occurs independent of protein kinase A and CREB but may involve Epac. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, F1395-F1401.	2.7	48
118	Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome?. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2100-2102.	0.7	47
119	Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents. <i>PLoS ONE</i> , 2012, 7, e39783.	2.5	47
120	New TRPC6 gain-of-function mutation in a non-consanguineous Dutch family with late-onset focal segmental glomerulosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1830-1838.	0.7	47
121	A European multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with Tacrolimus α -Rituximab versus steroids plus cyclophosphamide in patients with primary Membranous Nephropathy: the STARMEN study. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 503-510.	2.9	47
122	A retrospective study of focal segmental glomerulosclerosis: clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation. <i>BMC Nephrology</i> , 2013, 14, 47.	1.8	46
123	Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. <i>American Journal of Kidney Diseases</i> , 2017, 70, 770-777.	1.9	46
124	Vitamin D Down-Regulates TRPC6 Expression in Podocyte Injury and Proteinuric Glomerular Disease. <i>American Journal of Pathology</i> , 2013, 182, 1196-1204.	3.8	44
125	The Calcium-Dependent Protease Calpain-1 Links TRPC6 Activity to Podocyte Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2099-2109.	6.1	44
126	Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. <i>Liver International</i> , 2015, 35, 1607-1614.	3.9	43

#	ARTICLE	IF	CITATIONS
127	Acetazolamide Attenuates Lithium-Induced Nephrogenic Diabetes Insipidus. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2082-2091.	6.1	43
128	Alkylating agents in membranous nephropathy: efficacy proven beyond doubt. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1760-1766.	0.7	42
129	Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort. <i>BMC Nephrology</i> , 2012, 13, 20.	1.8	42
130	Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. <i>Clinical Immunology</i> , 2015, 160, 237-243.	3.2	42
131	Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. <i>Gastroenterology</i> , 2019, 157, 481-491.e7.	1.3	42
132	COLD PRESERVATION OF ISOLATED RABBIT PROXIMAL TUBULES INDUCES RADICAL-MEDIATED CELL INJURY1. <i>Transplantation</i> , 1998, 65, 625-632.	1.0	42
133	Prognostic Value of Risk Score and Urinary Markers in Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1242-1248.	4.5	41
134	Lithium reduces aquaporin-2 transcription independent of prostaglandins. <i>American Journal of Physiology - Cell Physiology</i> , 2012, 302, C131-C140.	4.6	41
135	Hypothermia causes a marked injury to rat proximal tubular cells that is aggravated by all currently used preservation solutions. <i>Cryobiology</i> , 2003, 47, 82-91.	0.7	40
136	Urinary heparanase activity in patients with Type 1 and Type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2853-2861.	0.7	40
137	Genetic Identification of Two Novel Loci Associated with Steroid-Sensitive Nephrotic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1375-1384.	6.1	40
138	Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2015, 66, 998-1005.	2.7	39
139	The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series. <i>American Journal of Kidney Diseases</i> , 2017, 69, 637-646.	1.9	39
140	Disposition and clinical implications of protein-bound uremic toxins. <i>Clinical Science</i> , 2017, 131, 1631-1647.	4.3	39
141	Rituximab in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021, 6, 881-893.	0.8	39
142	Hydrochlorothiazide attenuates lithium-induced nephrogenic diabetes insipidus independently of the sodium-chloride cotransporter. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, F525-F533.	2.7	38
143	The gelatin-derived plasma substitute Gelofusine causes low-molecular-weight proteinuria by decreasing tubular protein reabsorption. <i>Journal of Critical Care</i> , 2001, 16, 115-120.	2.2	37
144	Biomarker discovery with SELDI-TOF MS in human urine associated with early renal injury: evaluation with computational analytical tools. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2932-2943.	0.7	37

#	ARTICLE	IF	CITATIONS
145	Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3160-3165.	0.7	37
146	Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 88-97.	0.7	37
147	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. <i>Autoimmunity Reviews</i> , 2020, 19, 102671.	5.8	37
148	Proteomic Analysis Identifies Distinct Glomerular Extracellular Matrix in Collapsing Focal Segmental Glomerulosclerosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1883-1904.	6.1	37
149	MASTERPLAN: study of the role of nurse practitioners in a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients. <i>Journal of Nephrology</i> , 2008, 21, 261-7.	2.0	37
150	Estimation of Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease. <i>American Journal of Kidney Diseases</i> , 2015, 66, 792-801.	1.9	36
151	Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 635-645.	0.7	36
152	Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2020, 98, 989-998.	5.2	36
153	Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome. <i>American Journal of Kidney Diseases</i> , 2015, 65, 342.	1.9	35
154	Dissociation between urine osmolality and urinary excretion of aquaporinâ€² in healthy volunteers. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 1155-1161.	0.7	34
155	Serum ferritin levels are increased in patients with glomerular diseases and proteinuria. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2754-2760.	0.7	34
156	Quantitative Determination of Low and High Molecular Weight Proteins in Human Urine: Influence of Temperature and Storage Time. <i>Clinical Chemistry</i> , 1999, 45, 430-432.	3.2	32
157	Small increases in the urinary excretion of glutathione S-transferase A1 and P1 after cardiac surgery are not associated with clinically relevant renal injury. <i>Intensive Care Medicine</i> , 2005, 31, 664-667.	8.2	31
158	Phospholipase A2 Receptor Antibodies in Membranous Nephropathy: Unresolved Issues. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1137-1139.	6.1	31
159	Is increased erythrocyte sodium-lithium countertransport a useful marker for diabetic nephropathy?. <i>Kidney International</i> , 1992, 41, 862-871.	5.2	30
160	Podocyte changes upon induction of albuminuria in Thy-1.1 transgenic mice. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2524-2533.	0.7	30
161	Effect of shared care on blood pressure in patients with chronic kidney disease: a cluster randomised controlled trial. <i>British Journal of General Practice</i> , 2013, 63, e798-e806.	1.4	30
162	Familial nephropathy differing from minimal change nephropathy and focal glomerulosclerosis. <i>Kidney International</i> , 2001, 59, 693-701.	5.2	28

#	ARTICLE	IF	CITATIONS
163	Increased expression of lysosome membrane protein 2 in glomeruli of patients with idiopathic membranous nephropathy. <i>Proteomics</i> , 2015, 15, 3722-3730.	2.2	28
164	Acute phosphate depletion and in vitro rat proximal tubule injury: Protection by glycine and acidosis. <i>Kidney International</i> , 1992, 41, 1494-1500.	5.2	27
165	Antibody-induced albuminuria and accelerated focal glomerulosclerosis in the Thy-1.1 transgenic mouse. <i>Kidney International</i> , 2002, 62, 116-126.	5.2	27
166	Abnormal Vitamin D Metabolism and Loss of Bone Mass after Renal Transplantation. <i>Nephron Clinical Practice</i> , 2003, 93, c21-c28.	2.3	27
167	Membranous Nephropathy in the Older Adult. <i>Drugs and Aging</i> , 2007, 24, 717-732.	2.7	27
168	Tubular reabsorption and local production of urine hepcidin-25. <i>BMC Nephrology</i> , 2013, 14, 70.	1.8	27
169	Quality of chronic kidney disease management in primary care: a retrospective study. <i>Scandinavian Journal of Primary Health Care</i> , 2016, 34, 73-80.	1.5	27
170	Early Development of Hyperparathyroidism Due to Loss of <i>PTH</i> Transcriptional Repression in Patients With <i>HNF1β</i> Mutations?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4089-4096.	3.6	26
171	The bias between different albumin assays may affect clinical decision-making. <i>Kidney International</i> , 2019, 95, 1514-1517.	5.2	26
172	The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 251.	2.7	26
173	Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplantation. <i>Transplant International</i> , 2004, 17, 151-157.	1.6	26
174	Transcapillary escape rate of albumin is increased and related to haemodynamic changes in normo-albuminuric type 1 diabetic patients. <i>Journal of Hypertension</i> , 1999, 17, 1911-1916.	0.5	25
175	Renal proximal tubular dysfunction is a major determinant of urinary connective tissue growth factor excretion. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, F1457-F1464.	2.7	25
176	Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in <i>Cd37</i> -deficient mice. <i>Kidney International</i> , 2018, 93, 1356-1366.	5.2	25
177	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. <i>Kidney International</i> , 2021, 99, 671-685.	5.2	24
178	Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?. <i>Kidney International</i> , 2016, 89, 981-983.	5.2	23
179	Pharmacological treatment of primary membranous nephropathy in 2016. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1463-1478.	3.1	23
180	Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0142033.	2.5	23

#	ARTICLE	IF	CITATIONS
181	Effect of GFR on Plasma N-Terminal Connective Tissue Growth Factor (CTGF) Concentrations. <i>American Journal of Kidney Diseases</i> , 2012, 59, 619-627.	1.9	21
182	Longitudinal trends in thyroid function in relation to iodine intake: ongoing changes of thyroid function despite adequate current iodine status. <i>European Journal of Endocrinology</i> , 2014, 170, 49-54.	3.7	21
183	Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2036-2043.	0.7	20
184	Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3923-3929.	0.7	20
185	Demeclocycline attenuates hyponatremia by reducing aquaporin-2 expression in the renal inner medulla. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, F1705-F1718.	2.7	20
186	Uremic Solutes in Chronic Kidney Disease and Their Role in Progression. <i>PLoS ONE</i> , 2016, 11, e0168117.	2.5	20
187	Drug therapy management in patients with renal impairment: how to use creatinine-based formulas in clinical practice. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1433-1439.	1.9	20
188	1,25-Vitamin D3 Deficiency Induces Albuminuria. <i>American Journal of Pathology</i> , 2016, 186, 794-804.	3.8	20
189	Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i115-i122.	0.7	20
190	New technique to assess hypoxia-induced cell injury in individual isolated renal tubules. <i>Kidney International</i> , 1993, 43, 464-469.	5.2	19
191	Induction of albuminuria in mice: Synergistic effect of two monoclonal antibodies directed to different domains of aminopeptidase A. <i>Kidney International</i> , 1999, 55, 1335-1347.	5.2	19
192	Type I membranoproliferative glomerulonephritis in a renal allograft: A recurrence induced by a cytomegalovirus infection?. <i>American Journal of Kidney Diseases</i> , 2000, 35, e6.1-e6.7.	1.9	19
193	Atrial natriuretic peptide-induced microalbuminuria is associated with endothelial dysfunction in noncomplicated type 1 diabetes patients. <i>American Journal of Kidney Diseases</i> , 2002, 40, 9-15.	1.9	19
194	Effect of creatinine assay standardization on the performance of Cockcroft-Gault and MDRD formula in predicting GFR. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2998-2999.	0.7	19
195	Focal segmental glomerulosclerosis is not a sufficient predictor of renal outcome in patients with membranous nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2201-2207.	0.7	19
196	Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial. <i>Kidney International</i> , 2011, 80, 798-801.	5.2	19
197	Web-based consultation between general practitioners and nephrologists: a cluster randomized controlled trial. <i>Family Practice</i> , 2017, 34, 430-436.	1.9	19
198	Rationale and design of the MASTERPLAN study: Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. <i>Journal of Nephrology</i> , 2005, 18, 30-4.	2.0	19

#	ARTICLE	IF	CITATIONS
199	Estimated glomerular filtration rate in the nephrotic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 550-556.	0.7	18
200	Hypotonicity-induced Reduction of Aquaporin-2 Transcription in mpkCCD Cells Is Independent of the Tonicity Responsive Element, Vasopressin, and cAMP. <i>Journal of Biological Chemistry</i> , 2011, 286, 13002-13010.	3.4	18
201	The Biobank of Nephrological Diseases in the Netherlands cohort: the String of Pearls Initiative collaboration on chronic kidney disease in the university medical centers in the Netherlands. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1145-1150.	0.7	18
202	Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-11.	2.3	18
203	Neuropeptide Y and chronic kidney disease progression: a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1805-1812.	0.7	18
204	General practitioners' perspectives on management of early-stage chronic kidney disease: a focus group study. <i>BMC Family Practice</i> , 2018, 19, 81.	2.9	18
205	Prednisone-Induced Fluctuations of Proteinuria in Patients with a Nephrotic Syndrome. <i>Nephron</i> , 1986, 44, 344-350.	1.8	17
206	Podocyte Changes after Induction of Acute Albuminuria in Mice by Anti-Aminopeptidase A mAb. <i>Nephron Experimental Nephrology</i> , 2003, 94, e85-e93.	2.2	17
207	Angiotensin II Type 1 Receptor Activating Antibodies in Renal-Allograft Rejection. <i>New England Journal of Medicine</i> , 2005, 352, 2027-2028.	27.0	17
208	Anti-PLA2R1 Antibodies as Prognostic Biomarker in Membranous Nephropathy. <i>Kidney International Reports</i> , 2021, 6, 1677-1686.	0.8	17
209	Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. <i>BMC Nephrology</i> , 2012, 13, 17.	1.8	16
210	Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study. <i>Drug Safety</i> , 2017, 40, 153-167.	3.2	16
211	Human pluripotent stem cell-derived kidney organoids for personalized congenital and idiopathic nephrotic syndrome modeling. <i>Development (Cambridge)</i> , 2022, 149, .	2.5	16
212	Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: A nationwide survey in the Netherlands. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3534-3538.	0.7	15
213	Quality of care in patients with chronic kidney disease is determined by hospital specific factors. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3647-3654.	0.7	15
214	Kidney Dysfunction Increases Mortality and Incident Events after Young Stroke: The FUTURE Study. <i>Cerebrovascular Diseases</i> , 2016, 42, 224-231.	1.7	15
215	The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease. <i>American Journal of Nephrology</i> , 2017, 46, 239-248.	3.1	15
216	Outcome of renal transplantation in patients with systemic lupus erythematosus. <i>Transplant International</i> , 2003, 16, 411-418.	1.6	15

#	ARTICLE	IF	CITATIONS
217	The Natriuretic Effect of the Dihydropyridine Calcium Antagonist Felodipine. <i>Journal of Cardiovascular Pharmacology</i> , 1987, 10, S154-161.	1.9	15
218	The search goes on: suPAR is not the elusive FSGS factor. <i>Nature Reviews Nephrology</i> , 2014, 10, 431-432.	9.6	14
219	Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients. <i>Journal of Nephrology</i> , 2015, 28, 477-484.	2.0	14
220	Lithium-induced NDI: acetazolamide reduces polyuria but does not improve urine concentrating ability. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F669-F676.	2.7	14
221	Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire). <i>Patient</i> , 2017, 10, 629-642.	2.7	14
222	Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers. <i>Journal of Hypertension</i> , 1998, 16, 245-250.	0.5	13
223	Expression of sialidase and dystroglycan in human glomerular diseases. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 478-484.	0.7	13
224	Lifetime risk of renal replacement therapy in Europe: a population-based study using data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw392.	0.7	13
225	Adherence to chronic kidney disease guidelines in primary care patients is associated with comorbidity. <i>Family Practice</i> , 2017, 34, 459-466.	1.9	13
226	Effects of sildenafil, metformin, and simvastatin on ADH-independent urine concentration in healthy volunteers. <i>Physiological Reports</i> , 2018, 6, e13665.	1.7	13
227	Five non-mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes phenotype adult patients with m.3243A>G mutation after kidney transplantation: follow-up and review of the literature. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 840-846.	2.9	13
228	Nephrotic Syndrome With Mutations in NPHS2: The Role of R229Q and Implications for Genetic Counseling. <i>American Journal of Kidney Diseases</i> , 2019, 73, 400-403.	1.9	13
229	Albuminuria in Mice after Injection of Antibodies against Aminopeptidase A. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2711-2720.	6.1	13
230	Prednisolone can increase glomerular permeability to proteins in nephrotic syndrome. <i>Kidney International</i> , 1988, 33, 1169-1174.	5.2	12
231	Calcium Channel Blockers: Protective Effects in Ischemic Acute Renal Failure. <i>Renal Failure</i> , 1992, 14, 327-332.	2.1	12
232	Evidence for renal vasodilation in pre-dialysis patients during correction of anemia by erythropoietin. <i>Kidney International</i> , 1992, 41, 384-387.	5.2	12
233	Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232]. <i>Trials</i> , 2006, 7, 8.	1.6	12
234	Angiotensin converting enzyme inhibition prevents development of collapsing focal segmental glomerulosclerosis in Thy-1.1 transgenic mice. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3087-3097.	0.7	12

#	ARTICLE	IF	CITATIONS
235	Treatment-related changes in urinary excretion of high and low molecular weight proteins in patients with idiopathic membranous nephropathy and renal insufficiency. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 389-396.	0.7	12
236	Chronic kidney disease and mortality risk among older patients with type 2 diabetes mellitus (ZODIAC-24). <i>Age and Ageing</i> , 2012, 41, 345-350.	1.6	12
237	Urinary Connective Tissue Growth Factor Is Associated with Human Renal Allograft Fibrogenesis. <i>Transplantation</i> , 2013, 96, 494-500.	1.0	12
238	Prognostic models for chronic kidney disease: a systematic review and external validation. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1837-1850.	0.7	12
239	Novel <i>in vitro</i> assays to detect circulating permeability factor(s) in idiopathic focal segmental glomerulosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 247-256.	0.7	12
240	Thiazide Responsiveness Testing in Patients With Renal Magnesium Wasting and Correlation With Genetic Analysis: A Diagnostic Test Study. <i>American Journal of Kidney Diseases</i> , 2016, 68, 168-170.	1.9	11
241	Hypoxia decreases calcium influx into rat proximal tubules. <i>Kidney International</i> , 1998, 53, 703-708.	5.2	10
242	Deficiency of Either P-Glycoprotein or Breast Cancer Resistance Protein Protect against Acute Kidney Injury. <i>Cell Transplantation</i> , 2010, 19, 1195-1208.	2.5	10
243	Individualizing Pharmacotherapy in Patients with Renal Impairment: The Validity of the Modification of Diet in Renal Disease Formula in Specific Patient Populations with a Glomerular Filtration Rate below 60 ml/min. A Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0116403.	2.5	10
244	Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. <i>Nephrology (Saint-Petersburg)</i> , 2020, 24, 22-41.	0.4	10
245	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 291-303.	6.1	10
246	Influence of Albumin Infusion on the Urinary Excretion of \hat{I}^2 -Microglobulin in Patients with Proteinuria. <i>Nephron</i> , 1999, 81, 329-333.	1.8	9
247	Decreased renal excretion of soluble interleukin-2 receptor \hat{I}^2 after treatment with daclizumab. <i>Kidney International</i> , 2003, 64, 697-703.	5.2	9
248	Quantifying the benefit of early living-donor renal transplantation with a simulation model of the Dutch renal replacement therapy population. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 429-434.	0.7	9
249	Remote ischemic preconditioning to reduce contrast-induced nephropathy: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 119.	1.6	9
250	Differential Expression of Specific Dermatan Sulfate Domains in Renal Pathology. <i>PLoS ONE</i> , 2015, 10, e0134946.	2.5	9
251	What is the relationship between renal function and visit-to-visit blood pressure variability in primary care? Retrospective cohort study from routinely collected healthcare data. <i>BMJ Open</i> , 2016, 6, e010702.	1.9	9
252	What Patients with Mild-to-Moderate Kidney Disease Know, Think, and Feel about Their Disease: An In-Depth Interview Study. <i>Journal of the American Board of Family Medicine</i> , 2018, 31, 570-577.	1.5	9

#	ARTICLE	IF	CITATIONS
253	The zinc fingers and homeoboxes 2 protein ZHX2 and its interacting proteins regulate upstream pathways in podocyte diseases. <i>Kidney International</i> , 2020, 97, 753-764.	5.2	9
254	Worldwide Disparity in the Relation Between CKD Prevalence and Kidney Failure Risk. <i>Kidney International Reports</i> , 2020, 5, 2284-2291.	0.8	9
255	Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient. <i>Frontiers in Immunology</i> , 2020, 11, 612706.	4.8	9
256	Acute Effects of Nifedipine in Renal Transplant Recipients Treated With Cyclosporine or Azathioprine. <i>American Journal of Kidney Diseases</i> , 1994, 24, 838-845.	1.9	8
257	The fractional excretion of soluble interleukin-2 receptor-?? is an excellent predictor of the interleukin-2 receptor-?? status after treatment with daclizumab. <i>Transplantation</i> , 2004, 77, 281-286.	1.0	8
258	Expression and Effect of Inhibition of Aminopeptidase-A during Nephrogenesis. <i>Journal of Histochemistry and Cytochemistry</i> , 2006, 54, 253-262.	2.5	8
259	Adult and paediatric patients with minimal change nephrotic syndrome show no major alterations in glomerular expression of sulphated heparan sulphate domains. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2886-2893.	0.7	8
260	Serum suPAR concentrations in patients with focal segmental glomerulosclerosis with end-stage renal disease. <i>Kidney International</i> , 2014, 85, 711.	5.2	8
261	Clinical Relevance of Differences in Glomerular Filtration Rate Estimations in Frail Older People by Creatinine- vs. Cystatin C-Based Formulae. <i>Drugs and Aging</i> , 2017, 34, 445-452.	2.7	8
262	Unraveling Heparin Plasma Protein Binding: Evidence from Peritoneal Equilibration Testing. <i>Pharmaceuticals</i> , 2019, 12, 123.	3.8	8
263	Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy. <i>Kidney International</i> , 2022, 101, 646-647.	5.2	8
264	The Natriuretic Effect of the Dihydropyridine Calcium Antagonist Felodipine. <i>Journal of Cardiovascular Pharmacology</i> , 1987, 10, S154-161.	1.9	7
265	Primary Epstein-Barr virus infection and recurrent type I membranoproliferative glomerulonephritis after renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 1235-1237.	0.7	7
266	B Cell Suppression in Primary Glomerular Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 166-181.	1.4	7
267	Kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as prognostic markers in idiopathic membranous nephropathy. <i>Annals of Clinical Biochemistry</i> , 2016, 53, 51-57.	1.6	7
268	Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw391.	0.7	7
269	Standardized reporting of monoclonal immunoglobulin-associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. <i>Kidney International</i> , 2020, 98, 310-313.	5.2	7
270	Effects of renal cytoprotective agents on erythrocyte membrane stability. <i>Life Sciences</i> , 1998, 63, 975-983.	4.3	6

#	ARTICLE	IF	CITATIONS
271	Nephrotic syndrome associated with anti-tumor necrosis factor ? therapy in a patient with rheumatoid arthritis: Comment on the article by Charles et al. Arthritis and Rheumatism, 2002, 46, 1691-1693.	6.7	6
272	Iron chelators do not reduce cold-induced cell injury in the isolated perfused rat kidney model. Nephrology Dialysis Transplantation, 2005, 20, 2646-2653.	0.7	6
273	TRPC6 Single Nucleotide Polymorphisms and Progression of Idiopathic Membranous Nephropathy. PLoS ONE, 2014, 9, e102065.	2.5	6
274	Urinary biomarkers after donor nephrectomy. Transplant International, 2015, 28, 544-552.	1.6	6
275	Use of the Furosemide Fludrocortisone Test to Clinically Assess Distal Tubular Acidification. American Journal of Kidney Diseases, 2017, 70, 589-591.	1.9	6
276	The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment. Cellular and Molecular Immunology, 2020, 17, 653-655.	10.5	6
277	Later Response to Corticosteroids in Adults With Primary Focal Segmental Glomerular Sclerosis Is Associated With Favorable Outcomes. Kidney International Reports, 2022, 7, 87-98.	0.8	6
278	Kidney tubule iron loading in experimental focal segmental glomerulosclerosis. Scientific Reports, 2022, 12, 1199.	3.3	6
279	Angiotensin Converting Enzyme Inhibition Does Not Prevent the Natriuretic Effect of Felodipine. Journal of Cardiovascular Pharmacology, 1993, 21, 471-477.	1.9	5
280	Hepcidin Levels in Acute Kidney Injury Following Cardiopulmonary Bypass Grafting. American Journal of Kidney Diseases, 2009, 54, 979.	1.9	5
281	NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor. Molecular Omics, 2019, 15, 39-49.	2.8	5
282	Predicting kidney failure from longitudinal kidney function trajectory: A comparison of models. PLoS ONE, 2019, 14, e0216559.	2.5	5
283	Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Frontiers in Immunology, 2021, 12, 715704.	4.8	5
284	Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal. CKJ: Clinical Kidney Journal, 2021, 14, 1939-1945.	2.9	5
285	Evaluation of a closed perfusion chamber for single cell fluorescence measurements. Journal of Immunological Methods, 1991, 141, 289-291.	1.4	4
286	Treatment of recurrent focal glomerulosclerosis after renal transplantation: is prednisone essential to maintain a sustained remission?. Transplantation, 2003, 75, 1080-1081.	1.0	4
287	Cystatin C levels are unaltered in patients with diabetes mellitus and normal renal function. Kidney International, 2009, 76, 462.	5.2	4
288	Hepcidin levels in patients with renal disease. Kidney International, 2009, 76, 680.	5.2	4

#	ARTICLE	IF	CITATIONS
289	Impact of diffusion, ultrafiltration, and posture on total body electrical resistance in patients on hemodialysis. <i>Journal of Applied Physiology</i> , 2021, 130, 318-324.	2.5	4
290	Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies. <i>Frontiers in Immunology</i> , 2021, 12, 676662.	4.8	4
291	Parietal epithelial cells maintain the epithelial cell continuum forming Bowman's space in focal segmental glomerulosclerosis. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	2.4	4
292	Renal outcomes in the ONTARGET study. <i>Lancet, The</i> , 2008, 372, 2020.	13.7	3
293	Blood Pressure Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 695-697.	27.0	3
294	Impact on cardiovascular risk follow-up from a shift to the CKD-EPI formula for eGFR reporting: a cross-sectional population-based primary care study. <i>BMJ Open</i> , 2013, 3, e003631.	1.9	3
295	New advances in the treatment of glomerular disease. <i>Nature Reviews Nephrology</i> , 2017, 13, 65-66.	9.6	3
296	Reference values of renal tubular function tests are dependent on age and kidney function. <i>Physiological Reports</i> , 2017, 5, e13542.	1.7	3
297	Differential diagnosis of thrombotic microangiopathy in nephrology. <i>BMC Nephrology</i> , 2017, 18, 324.	1.8	3
298	Urinary Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor Binding Protein 7 Do Not Correlate With Disease Severity in ADPKD Patients. <i>Kidney International Reports</i> , 2019, 4, 833-841.	0.8	3
299	Inhibition of mTOR delayed but could not prevent experimental collapsing focal segmental glomerulosclerosis. <i>Scientific Reports</i> , 2020, 10, 8580.	3.3	3
300	Low plasma magnesium concentration and future abdominal aortic calcifications in moderate chronic kidney disease. <i>BMC Nephrology</i> , 2021, 22, 71.	1.8	3
301	Rituximab is preferable to cyclophosphamide for treatment of membranous nephropathy: CON. <i>Kidney360</i> , 2021, 2, 10.34067/KID.0001432021.	2.1	3
302	Serum albumin measurement in nephrology: room for improvement. <i>Nephrology Dialysis Transplantation</i> , 2020, , .	0.7	3
303	Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 362-371.	0.7	3
304	Motile Cilia on Kidney Proximal Tubular Epithelial Cells Are Associated With Tubular Injury and Interstitial Fibrosis. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 765887.	3.7	3
305	COVID-19 Vaccination in Patients With Membranous Nephropathy. <i>Kidney International Reports</i> , 2022, 7, 1922-1923.	0.8	3
306	Prevention and attenuation of acute renal failure. <i>Current Opinion in Nephrology and Hypertension</i> , 1992, 1, 133-140.	2.0	2

#	ARTICLE	IF	CITATIONS
307	Induced Alterations in Calcium Uptake Rate in Normoxic Rat Proximal Tubules. <i>Renal Failure</i> , 1995, 17, 503-515.	2.1	2
308	Epitope Mapping of Monoclonal Antibodies Directed to Aminopeptidase A and Their Relevance for Albuminuria in Mice. <i>Nephron Experimental Nephrology</i> , 2003, 94, e25-e34.	2.2	2
309	New Insights Into the Pathogenesis and the Therapy of Recurrent Focal Glomerulosclerosis. <i>American Journal of Transplantation</i> , 2005, 5, 2594-2594.	4.7	2
310	Differences between hospitals in attainment of parathyroid hormone treatment targets in chronic kidney disease do not reflect differences in quality of care. <i>BMC Nephrology</i> , 2012, 13, 82.	1.8	2
311	Measurement of serum suPAR is not ready for clinical use. <i>Nature Reviews Nephrology</i> , 2014, 10, 610-610.	9.6	2
312	Central arteriovenous anastomosis and hypertension. <i>Lancet, The</i> , 2015, 386, 1821.	13.7	2
313	Rituximab can induce remission of nephrotic syndrome in the absence of peripheral B-cells. <i>Nephrology</i> , 2015, 20, 667-668.	1.6	2
314	Urinary Excretion of $\hat{1} \pm 1$ -Microglobulin Does Not Predict Graft Loss in Stable Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2017, 70, 151.	1.9	2
315	Antibodies Against M-Type Phospholipase Receptor and Prediction of Outcome in Membranous Nephropathy: We are Not There Yet. <i>American Journal of Nephrology</i> , 2018, 48, 434-437.	3.1	2
316	Urine Acidification After Ammonium Chloride. <i>American Journal of Kidney Diseases</i> , 2018, 72, 909-911.	1.9	2
317	Establishment and characterization of a novel conditionally immortalized human parietal epithelial cell line. <i>Experimental Cell Research</i> , 2021, 405, 112712.	2.6	2
318	Atheroembolic Disease in a Female Patient. <i>Circulation</i> , 1997, 96, 700-700.	1.6	2
319	A Vasopressin-Induced Change in Prostaglandin Receptor Subtype Expression Explains the Differential Effect of PGE2 on AQP2 Expression. <i>Frontiers in Physiology</i> , 2021, 12, 787598.	2.8	2
320	Monoclonal gammopathy of renal significance presenting with cryoglobulinaemia type I associated severe thrombotic microangiopathy. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1425-1428.	2.9	2
321	Kidney Injury in Patients Treated with Immune Checkpoint Inhibitors Does Not Meet KDIGO-AKI Criteria. <i>Kidney360</i> , 2022, 3, 524-529.	2.1	2
322	Eculizumab impairs killing of <i>Neisseria meningitidis</i> serogroup B in atypical hemolytic uremic syndrome patients vaccinated with MenB-4C. <i>Kidney International</i> , 2022, 101, 1293-1295.	5.2	2
323	Response to \hat{e} proteinuria in normal cadaver kidney donors \hat{e} . <i>Transplantation</i> , 2003, 76, 439-440.	1.0	1
324	Letter by Wetzels Regarding Article, \hat{e} Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A Randomized Comparison of 3 Preventive Strategies \hat{e} . <i>Circulation</i> , 2007, 116, e310; author reply e311.	1.6	1

#	ARTICLE	IF	CITATIONS
325	Rituximab for plasma exchange-dependent recurrent focal segmental glomerulosclerosis after renal transplantation. CKJ: Clinical Kidney Journal, 2008, 1, 85-88.	2.9	1
326	Immunosuppression for membranous nephropathy. Lancet, The, 2013, 381, 2162.	13.7	1
327	Maintenance of steroid-free remission in nephrotic syndrome. Nature Reviews Nephrology, 2015, 11, 569-570.	9.6	1
328	Kidney Weight in Living and Postmortal Kidney Donation. Transplantation, 2016, 100, e1-e2.	1.0	1
329	Pharmacokinetics and pharmacodynamics of eculizumab in individualized treatment of atypical hemolytic uremic syndrome. Immunobiology, 2016, 221, 1141.	1.9	1
330	Prostaglandins in thiazide-induced hyponatraemia: do they hold water?. Nature Reviews Nephrology, 2017, 13, 665-666.	9.6	1
331	SaO018FACTOR D INHIBITION WITH ACH-4471 TO REDUCE COMPLEMENT ALTERNATIVE PATHWAY HYPERACTIVITY AND PROTEINURIA IN C3 GLOMERULOPATHY: PRELIMINARY PROOF OF CONCEPT DATA. Nephrology Dialysis Transplantation, 2018, 33, i322-i322.	0.7	1
332	The authors reply. Kidney International, 2019, 96, 249.	5.2	1
333	Treatment-resistant nephrotic syndrome in dense deposit disease: complement-mediated glomerular capillary wall injury?. Pediatric Nephrology, 2020, 35, 1791-1795.	1.7	1
334	The authors reply. Kidney International, 2022, 101, 187.	5.2	1
335	Accuracy of Bioimpedance Spectroscopy in the Detection of Hydration Changes in Patients on Hemodialysis. , 2023, 33, 193-200.		1
336	Screening for microalbuminuria. Kidney International, 2005, 68, 1899-1900.	5.2	0
337	Cyclophosphamide plus steroids for membranous nephropathy with nephrotic syndrome: long-term outcomes. Nature Clinical Practice Nephrology, 2007, 3, 534-535.	2.0	0
338	Urinary albumin:total protein ratioâ€”a new diagnostic tool to differentiate glomerular from nonglomerular hematuria. Nature Clinical Practice Nephrology, 2008, 4, 590-591.	2.0	0
339	The authors reply. Kidney International, 2018, 94, 830.	5.2	0
340	SaO003USE OF THIAZIDE DIURETICS DOES NOT WORSEN DISEASE PROGRESSION IN ADPKD. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
341	FP641PERFORMANCE AND PITFALLS OF THE FRESENIUSÂ® BODY COMPOSITION MONITOR FOR WATER BALANCE MANAGEMENT IN PATIENTS ON HEMODIALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
342	FP196NOVEL ELISA FOR THSD7A AUTOANTIBODIES IN MEMBRANOUS NEPHROPATHY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0

#	ARTICLE	IF	CITATIONS
343	Author's Reply to Liu et al.: Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clinical Pharmacokinetics, 2020, 59, 1645-1646.	3.5	0
344	Functional tests to guide management in an adult with loss of function of type-1 angiotensin II receptor. Pediatric Nephrology, 2021, 36, 2731-2737.	1.7	0
345	Glomerular Outgrowth as an Ex Vivo Assay to Analyze Pathways Involved in Parietal Epithelial Cell Activation. Journal of Visualized Experiments, 2020, , .	0.3	0
346	Referring patients with stable moderate to advanced chronic kidney disease back to primary care: a feasibility study. BJGP Open, 2022, , BJGPO.2021.0177.	1.8	0
347	MO168: Urinary Podocin Cell Count in Relation to Glomerular Damage Markers in Patients with Primary Nephrotic Syndrome. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
348	Diagnosis and Treatment of Patients With FSGS/SRNS: A Delphi Survey. Kidney International Reports, 2022, , .	0.8	0